30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
JP Pharmaceuticals

Takeda Pharmaceutical Co Ltd (4502)

Track

Recent insider transactions at Takeda Pharmaceutical Co Ltd primarily consist of proposed sales by senior executives, including the CEO and Presidents of various business units. The most recent trading activity occurred in December 2025, with significant proposed sales also noted in July 2025. These transactions represent a consistent pattern of executive divestitures.
Stock chart
Ticker: 4502 Exchange: TYO
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Lauren Rusckowski Duprey
Chief Human Resources Officer
1 sale — total 421,182 USD
Proposed sale 9 Dec 2025
Value US$4,204,569.73 | Price 126.86 | Shares 41,998
Proposed sale 5 Dec 2025
Value US$2,732,424.12 | Price 105.02 | Shares 96,599
Proposed sale 4 Dec 2025
Value US$836,004.51 | Price 14.31 | Shares 58,421
Proposed sale 9 Jul 2025
Value US$537,494.94 | Price 15.42 | Shares 34,857
Proposed sale 9 Jul 2025
Value US$86,475.36 | Price 15.42 | Shares 5,608
Proposed sale 9 Jul 2025
Value US$69,035.34 | Price 15.42 | Shares 4,477
Proposed sale 9 Jul 2025
Value US$287,151.24 | Price 15.42 | Shares 18,622
Proposed sale 9 Jul 2025
Value US$414,397.08 | Price 15.42 | Shares 26,874
Proposed sale 9 Jul 2025
Value US$630,970.98 | Price 15.42 | Shares 40,919
Proposed sale 9 Jul 2025
Value US$94,617.12 | Price 15.42 | Shares 6,136
Proposed sale 9 Jul 2025
Value US$902,979.78 | Price 15.42 | Shares 58,559
Proposed sale 9 Jul 2025
Value US$2,610,806.46 | Price 15.42 | Shares 169,313
Proposed sale 9 Jul 2025
Value US$440,271.84 | Price 15.42 | Shares 28,552
Proposed sale 9 Jul 2025
Value US$811,847.58 | Price 15.42 | Shares 52,649
Proposed sale 9 Jul 2025
Value US$1,587,828.24 | Price 15.42 | Shares 102,972
Proposed sale 23 Aug 2024
Value US$284,950.62 | Price 14.94 | Shares 19,073
Proposed sale 11 Jul 2024
Value US$59,744.94 | Price 13.18 | Shares 4,533
Proposed sale 11 Jul 2024
Value US$507,153.22 | Price 13.18 | Shares 38,479
Proposed sale 11 Jul 2024
Value US$983,939.72 | Price 13.18 | Shares 74,654
Proposed sale 11 Jul 2024
Value US$140,683.32 | Price 13.18 | Shares 10,674
Proposed sale 11 Jul 2024
Value US$363,807.54 | Price 13.18 | Shares 27,603
Proposed sale 11 Jul 2024
Value US$490,546.42 | Price 13.18 | Shares 37,219
Proposed sale 11 Jul 2024
Value US$273,102.78 | Price 13.18 | Shares 20,721
Proposed sale 11 Jul 2024
Value US$80,819.76 | Price 13.18 | Shares 6,132
Proposed sale 11 Jul 2024
Value US$60,786.16 | Price 13.18 | Shares 4,612
Proposed sale 11 Jul 2024
Value US$196,250.20 | Price 13.18 | Shares 14,890
Proposed sale 11 Jul 2024
Value US$1,596,427.50 | Price 13.18 | Shares 121,125
Proposed sale 11 Jul 2024
Value US$79,712.64 | Price 13.18 | Shares 6,048
Proposed sale 11 Jul 2023
Value US$74,133.84 | Price 15.48 | Shares 4,789
Proposed sale 11 Jul 2023
Value US$718,644.64 | Price 15.48 | Shares 46,424
Proposed sale 11 Jul 2023
Value US$1,055,490.39 | Price 15.48 | Shares 68,184
Proposed sale 11 Jul 2023
Value US$31,654.34 | Price 15.48 | Shares 2,045
Proposed sale 11 Jul 2023
Value US$162,873.72 | Price 15.48 | Shares 10,522
Proposed sale 11 Jul 2023
Value US$166,130.52 | Price 15.48 | Shares 10,732
Proposed sale 11 Jul 2023
Value US$455,154.26 | Price 15.48 | Shares 29,403
Proposed sale 11 Jul 2023
Value US$377,620.01 | Price 15.48 | Shares 24,394
Proposed sale 11 Jul 2023
Value US$480,888.97 | Price 15.48 | Shares 31,065
Proposed sale 11 Jul 2023
Value US$2,140,334.39 | Price 15.48 | Shares 138,264
Proposed sale 11 Jul 2023
Value US$146,076.06 | Price 15.48 | Shares 9,436
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-09 2025-12-09 PrS Proposed sale
Lauren Rusckowski Duprey

Chief Human Resources Officer

Officer
41,998
126.86
US$4,204,570 		41,998 126.86 US$4,204,570
2025-12-05 2025-12-05 PrS Proposed sale
Teresa Marie Bitetti

President, Global Oncology Business Unit
96,599
105.02
US$2,732,424 		96,599 105.02 US$2,732,424
2025-12-04 2025-12-04 PrS Proposed sale
Giles Richard Platford

President, Plasma-Derived Therapies Business Unit
17,703
248.85
US$2,113,330 		17,703 248.85 US$2,113,330
2025-07-09 2025-07-09 PrS Proposed sale
Christophe Pierre Weber

Chief Executive Officer

Officer
34,857
15.42
US$537,495 		34,857 15.42 US$537,495
2025-07-09 2025-07-09 PrS Proposed sale
Akiko Amakawa

Corporate Strategy Officer & CEO Chief of Staff

Officer
5,608
15.42
US$86,475 		5,608 15.42 US$86,475
2025-07-09 2025-07-09 PrS Proposed sale
Elaine Mary Shannon

Global Quality Officer

Officer
4,477
15.42
US$69,035 		4,477 15.42 US$69,035
2025-07-09 2025-07-09 PrS Proposed sale
Marcello Pignagnoli Agosti

Global Business Development Officer

Officer
18,622
15.42
US$287,151 		18,622 15.42 US$287,151
2025-07-09 2025-07-09 PrS Proposed sale
Gabriele Ricci

Chief Data & Technology Officer

Officer
26,874
15.42
US$414,397 		26,874 15.42 US$414,397
2025-07-09 2025-07-09 PrS Proposed sale
Lauren Rusckowski Duprey

Chief Human Resources Officer

Officer
40,919
15.42
US$630,971 		40,919 15.42 US$630,971
2025-07-09 2025-07-09 PrS Proposed sale
Thomas Wozniewski

Global Manufacturing & Supply Officer

Officer
6,136
15.42
US$94,617 		6,136 15.42 US$94,617
2025-07-09 2025-07-09 PrS Proposed sale
Julie Kim

President, US Business Unit
58,559
15.42
US$902,980 		58,559 15.42 US$902,980
2025-07-09 2025-07-09 PrS Proposed sale
Andrew Plump

President, Research & Development
169,313
15.42
US$2,610,806 		169,313 15.42 US$2,610,806
2025-07-09 2025-07-09 PrS Proposed sale
Giles Richard Platford

President, Plasma-Derived Therapies Business Unit
28,552
15.42
US$440,272 		28,552 15.42 US$440,272
2025-07-09 2025-07-09 PrS Proposed sale
Teresa Marie Bitetti

President, Global Oncology Business Unit
52,649
15.42
US$811,848 		52,649 15.42 US$811,848
2025-07-09 2025-07-09 PrS Proposed sale
Ramona A Sequeira

President, Global Portfolio Division
102,972
15.42
US$1,587,828 		102,972 15.42 US$1,587,828
2024-08-22 2024-08-23 PrS Proposed sale
Giles Richard Platford

President, Plasma-Derived Therapies Business Unit
19,073
14.94
US$284,951 		19,073 14.94 US$284,951
2024-07-10 2024-07-11 PrS Proposed sale
Thomas Wozniewski

Global Manufacturing & Supply Officer

Officer
4,533
13.18
US$59,745 		4,533 13.18 US$59,745
2024-07-10 2024-07-11 PrS Proposed sale
Teresa Marie Bitetti

President, Global Oncology Business Unit
38,479
13.18
US$507,153 		38,479 13.18 US$507,153
2024-07-10 2024-07-11 PrS Proposed sale
Ramona A Sequeira

President, Global Portfolio Division
74,654
13.18
US$983,940 		74,654 13.18 US$983,940
2024-07-10 2024-07-11 PrS Proposed sale
Marcello Pignagnoli Agosti

Global Business Development Officer

Officer
10,674
13.18
US$140,683 		10,674 13.18 US$140,683
2024-07-10 2024-07-11 PrS Proposed sale
Lauren Rusckowski Duprey

Chief Human Resources Officer

Officer
27,603
13.18
US$363,808 		27,603 13.18 US$363,808
2024-07-10 2024-07-11 PrS Proposed sale
Julie Kim

President, US Business Unit
37,219
13.18
US$490,546 		37,219 13.18 US$490,546
2024-07-10 2024-07-11 PrS Proposed sale
Giles Richard Platford

President, Plasma-Derived Therapies Business Unit
20,721
13.18
US$273,103 		20,721 13.18 US$273,103
2024-07-10 2024-07-11 PrS Proposed sale
Gabriele Ricci

Chief Data & Technology Officer

Officer
6,132
13.18
US$80,820 		6,132 13.18 US$80,820
2024-07-10 2024-07-11 PrS Proposed sale
Elaine Mary Shannon

Global Quality Officer

Officer
4,612
13.18
US$60,786 		4,612 13.18 US$60,786
2024-07-10 2024-07-11 PrS Proposed sale
Christophe Pierre Weber

Chief Executive Officer

Officer
14,890
13.18
US$196,250 		14,890 13.18 US$196,250
2024-07-10 2024-07-11 PrS Proposed sale
Andrew Plump

President, Research & Development
121,125
13.18
US$1,596,428 		121,125 13.18 US$1,596,428
2024-07-10 2024-07-11 PrS Proposed sale
Akiko Amakawa

Corporate Strategy Officer & CEO Chief of Staff

Officer
6,048
13.18
US$79,713 		6,048 13.18 US$79,713
2023-07-10 2023-07-11 PrS Proposed sale
Thomas Wozniewski

Global Manufacturing & Supply Officer

Officer
4,789
15.48
US$74,134 		4,789 15.48 US$74,134
2023-07-10 2023-07-11 PrS Proposed sale
Teresa Marie Bitetti

President, Global Oncology Business Unit
46,424
15.48
US$718,645 		46,424 15.48 US$718,645
2023-07-10 2023-07-11 PrS Proposed sale
Ramona A Sequeira

President, Global Portfolio Division
68,184
15.48
US$1,055,490 		68,184 15.48 US$1,055,490
2023-07-10 2023-07-11 PrS Proposed sale
Mwana Lugogo

Chief Ethics & Compliance Officer

Officer
2,045
15.48
US$31,654 		2,045 15.48 US$31,654
2023-07-10 2023-07-11 PrS Proposed sale
Marcello Pignagnoli Agosti

Global Business Development Officer

Officer
10,522
15.48
US$162,874 		10,522 15.48 US$162,874
2023-07-10 2023-07-11 PrS Proposed sale
Lauren Duprey

Chief Human Resources Officer

Officer
10,732
15.48
US$166,131 		10,732 15.48 US$166,131
2023-07-10 2023-07-11 PrS Proposed sale
Julie Kim

President, US Business Unit
29,403
15.48
US$455,154 		29,403 15.48 US$455,154
2023-07-10 2023-07-11 PrS Proposed sale
Giles Richard Platford

President, Plasma-Derived Therapies Business Unit
24,394
15.48
US$377,620 		24,394 15.48 US$377,620
2023-07-10 2023-07-11 PrS Proposed sale
Gerard M Greco

Global Quality Officer

Officer
31,065
15.48
US$480,889 		31,065 15.48 US$480,889
2023-07-10 2023-07-11 PrS Proposed sale
Andrew Plump

President, Research & Development
138,264
15.48
US$2,140,334 		138,264 15.48 US$2,140,334
2023-07-10 2023-07-11 PrS Proposed sale
Gabriele Ricci

Chief Data & Technology Officer

Officer
9,436
15.48
US$146,076 		9,436 15.48 US$146,076
Explore more

More insider trading research around Takeda Pharmaceutical Co Ltd

More insider trades in JP
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity